Combine is a multicenter, randomized clinical trial that will evaluate combinations of three interventions for treating alcohol dependence. The goal is to determine whether improvement in treatment outcomes can be achieved by various combinations of drug and behavioral interventions. Two of the interventions will consist of pharmacological treatment with naltrexone (Revia) or acamprosate (Campral). The third intervention is a multicomponent behavioral therapy including such components as motivational enhancement therapy, cognitive behavioral therapy, and referral to self-help groups, including AA. All three interventions will include a component supporting compliance to medications and reduction in drinking.

Condition	Treatment or Intervention	Phase
Alcoholism	Drug: naltrexone (Revia)  Drug: acamprosate (Campral)	Phase III

Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Both

Criteria

The study has specific inclusion/exclusion criteria that limit participation. To learn more, interested individuals should contact the recruitment coordinator of the site nearest them.

Connecticut
      Substance Abuse Treatment Unit, Yale University, New Haven,  Connecticut,  06511,  United States
Florida
      University of Miami School of Medicine, Miami,  Florida,  33136,  United States
Massachusetts
      Boston University School of Medicine, Boston,  Massachusetts,  02118,  United States
      Harvard University/McLean Hospital, Belmont,  Massachusetts,  02478,  United States
      Massachusetts General Hospital, Boston,  Massachusetts,  02114,  United States
New Mexico
      Center on Alcoholism, Substance Abuse and Addiction, University of New Mexico, Albuquerque,  New Mexico,  87106,  United States
Pennsylvania
      Treatment and Research Center, University of Pennsylvania, Philadelphia,  Pennsylvania,  19104,  United States
Rhode Island
      Roger Williams Medical Center , Brown University, Providence,  Rhode Island,  02908,  United States
South Carolina
      Center for Alcohol Programs, Medical University of South Carolina, Charleston,  South Carolina,  29425,  United States
Texas
      Southwest Texas Addiction Research and Technology Center, University of Texas Health Science Center, San Antonio,  Texas,  78229,  United States
Washington
      Addictions Treatment Center, University of Washington, Seattle,  Washington,  98108,  United States
Wisconsin
      University of Wisconsin-Milwaukee, Milwaukee,  Wisconsin,  53233,  United States

Study ID Numbers:  NIAAAComb; U10AA11783; U10AA11715; U10AA11799; U10AA11773; U10AA11776; U10AA11777; U10AA11727; U10AA11716; U10AA11787; U10AA11768; U10AA11756
Record last reviewed:  April 2004
Record first received:  September 11, 2000
ClinicalTrials.gov Identifier:  NCT00006206
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2004-10-14